The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | Combining pirtobrutinib with established regimens for the treatment of CLL
Catherine Coombs, MD, UC Irvine Health, Orange County, CA, discusses how pirtobrutinib is being combined with other agents for the treatment of chronic lymphocytic leukemia (CLL) in clinical trials. While there are currently no completed studies comparing pirtobrutinib combinations to established treatment regimens, Dr Coombs is excited to see the results of several upcoming trials that will provide valuable insights in this space. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we don’t have any completed studies with comparative data. However, what I can say is that I’m excited to see the results whenever they do come out, which I would expect would be another year or two from another phase three BRUIN program, which is pirto plus venR versus venR alone asking the question is the addition of a non-covalent inhibitor to an effective relapse regimen, venR, going to lead to a better patient outcomes...
So we don’t have any completed studies with comparative data. However, what I can say is that I’m excited to see the results whenever they do come out, which I would expect would be another year or two from another phase three BRUIN program, which is pirto plus venR versus venR alone asking the question is the addition of a non-covalent inhibitor to an effective relapse regimen, venR, going to lead to a better patient outcomes.
There was also some really exciting data from MD Anderson looking at pirto in the frontline combined with venO. However, there’s no comparator arm in that study, so we can’t really say pirto-venO is better than venO alone. You’d need a phase three study. There will be an exciting study led by the German CLL group of venO versus P plus V. And there’s two PV arms: one is time-limited, fixed-duration, the other is MRD-directed. So that one will obviously take quite a while to read out. I think it’s just starting to accrue, but that’ll be very interesting to see can we move pirto to the front line as a time-limited regimen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie, AstraZeneca, BeOne Medicines, Lilly, Genentech, Janssen.
